Table 1.
ABRACL expression in 147 primary colorectal cancer specimens.
| Clinicopathological Characteristics |
ABRACL Expression a | p Value c | ||||
|---|---|---|---|---|---|---|
| High | Low | |||||
| Group | n | n | (%) | n | (%) | |
| Total | 147 | |||||
| Gender | ||||||
| Male | 86 | 29 | (33.7) | 57 | (66.3) | NS d |
| Female | 61 | 21 | (34.4) | 40 | (65.6) | |
| Age b (y) | ||||||
| 66 and older | 68 | 24 | (35.3) | 44 | (64.7) | NS d |
| Less than 66 | 79 | 26 | (32.9) | 53 | (67.1) | |
| Metastasis | ||||||
| M(+) | 111 | 46 | (41.4) | 65 | (58.6) | 0.002 ** |
| M(−) | 36 | 4 | (11.1) | 32 | (88.9) | |
a Intensity of staining was scored by pathologists (0, absent; 1, weak; 2, moderate; and 3, strong; representative examples are shown in Figure 8B); the scores of 0–1 and 2–3 were defined as low and high expression, respectively. b Divided into 2 groups by the median age; c χ2 test; d not significant (p > 0.05); ** statistically significant (p < 0.01).